Supporting Information available

Sustainable Byproduct Catalyzed Domino Strategy: Facile Synthesis of α- formyloxy and Acetoxy Ketones via Iodination/Nucleophilic

Substitution/Hydrolyzation/Oxidation Sequences

Yan-Ping Zhu, Qing-He Gao, Mi Lian, Jing-Jing Yuan, Mei-Cai Liu, Qin Zhao, Yan Yang, An-Xin Wu*

Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, Central China Normal University, Wuhan 430079, P. R. China

E-mail: chwuax@mail.ccnu.edu.cn

Table of Contents

Pages

1.	General							.S2
2.	Synthesis of 3a-3m, 5a-5f S2							
3.	Evidence	in	support		of	the	hypot	hetic
	mechanism		S2-S5					
4.	Crystallographic data and molecular structure						S5-S6	
5.	Spectral dat	ta of comp	oound 3a-	- 3m ,	5a-5f.			
	S6-S12							
6.	Appendix:	spectral	copies	of	$^{1}\mathrm{H}$	NMR,	and	$^{13}\mathrm{C}$
	NMR	S12-S	48					

1. General

All aryl methyl ketones (**1a-1n**), and other reagents were obtained from commercial suppliers and used without further purification. TLC analysis was performed using pre-coated glass plates. Column chromatography was performed using silica gel (200-300 mesh). IR spectra were recorded on a Perkin-Elmer PE-983 infrared spectrometer as KBr pellets with absorption in cm⁻¹. ¹H NMR spectra were recorded on a Varian Mercury 400 or 600 MHz spectrometer Chemical shifts are reported in ppm, relative to the internal standard of tetramethylsilane (TMS). HRMS were obtained on a Bruker 7-tesla FT-ICR MS equipped with an electrospray source. The X-ray crystal-structure determinations of **2e** and **3d** were obtained on a Bruker SMART APEX CCD system. Melting points were determined using XT-4 apparatus and not corrected.

2. Synthesis of 2a-2x, 3a-3m

2.1. General procedure for preparation of 2 and 3 (2b as an example)

A mixture of benzalacetone **1b** (120 mg, 1 mmol), iodine (254 mg, 1.0 mmol), and CuO (80 mg, 1.0 mmol) in common DMF (3.0 mL) was heated at 110 $^{\circ}$ C for 1 h, after disappearance of the reactant (monitored by TLC), and added 50mL water to the residue, then extracted with EtOAc 3 times (3 × 50mL). The extract was washed with 10% Na₂S₂O₃, dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography on silica gel using petroleum ether/EtOAc as the eluent to give the expected products **2b** in 96% yield.

3. In order to support the hypothetic mechanism following experiments were carried out.

(a) The reaction process of Acetophenone **1a**, iodine and CuO in DMF at 110 °C: The reaction process of acetophenone **1a** (120 mg, 1.0 mmol), iodine (254 mg, 1.0 mmol) and CuO (80 mg, 1.0 mmol) in DMF (6mL) at 110°C was monitored by 1H NMR (400 MHz, CDCl₃, 298 K) over time.





(b) A mixture of phenacyl iodine (246 mg, 1.0 mmol), I_2 (253.81 mg, 1.0 mmol), and CuO (80 mg, 1.0 mmol) in DMF (3-4 mL) was stirred at 110°C for 2 h. After the reaction completed, the reaction mixture was filtered, diluted with water and extracted with EtOAc (3×20 mL). The extract was washed with Na₂S₂O₃ (5% w/w, aq.), and brine successively. After drying over Na₂SO₄ and evaporation, the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc) to afford the product 2a (>95% yield) as a yellow oil.



(c) The isotope labeling experiment

1. A mixture of 1-(4-methoxyphenyl)ethanone (150.17 mg, 1.0 mmol), I₂ (253.81 mg, 1.0 mmol), and CuO (80 mg, 1.0 mmol) in DMF (3-4 mL) was stirred at 110°C for 2 h. After the reaction completed, the reaction mixture was filtered, diluted with water and extracted with EtOAc (3×20 mL). The extract was washed with Na₂S₂O₃ (5% w/w, aq.), and brine successively. After drying over Na₂SO₄ and evaporation, the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc) to afford the product 2a (>95% yield).



2. A mixture of 1-(4-methoxyphenyl)ethanone (150.17 mg, 1.0 mmol), I₂ (253.81 mg, 1.0 mmol), CuO (80 mg, 1.0 mmol) and 0.15mL H₂O (O¹⁸>90%) in anhydrous DMF (3-4 mL) under the Ar atmosphere was stirred at 110°C for 4 h. After the reaction completed, the reaction mixture was filtered, diluted with water and extracted with EtOAc (3×20 mL). The extract was washed with Na₂S₂O₃ (5% w/w, aq.), and brine successively. After drying over Na₂SO₄ and evaporation, the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc) to afford the product **3c'** (92% yield)





3. A mixture of 4-methoxyphenacyl iodine (246 mg, 1.0 mmol), CuI (190 mg, 1.0 mmol) and 0.15mL H₂O (O¹⁸>90%) in anhydrous DMF (3-4 mL) under the Ar atmosphere was stirred at 110°C for 4 h. After the reaction completed, the reaction mixture was filtered, diluted with water and extracted with EtOAc (3×20 mL). The extract was washed with Na₂S₂O₃ (5% w/w, aq.), and brine successively. After drying over Na₂SO₄ and evaporation, the crude product was purified by column chromatography on silica gel (eluent: petroleum ether/EtOAc) to afford the product **3c**" (>95% yield).



4. Crystallographic data and molecular structure

Crystal structure data for macrocycle 2e: CCDC 844753.

 $C_9H_7NO_5$, chemical formula weight: 209.16, Orthorhombic space group P2(1)/c, a = 9.6790(1), b = 15.1737(15), c = 6.3703(6) Å; $\alpha = 90.00^\circ$, $\beta = 92.00^\circ$, $\gamma = 90.00^\circ$, U = 927.02(16) Å3, T = 298(2) K, Z = 4, DC = 1.499 Mg/M³, $\mu = 0.125$ mm⁻¹, $\lambda = 0.71073$ Å, F(000) 432, crystal size $0.20 \times 0.10 \times 0.10$ mm³, 2289 independent reflections[R(int) = 0.1244], reflections collected 11219, refinementmethod: full-matrix least-squares on F²: goodness-of-fit on F² 1.049, final R indices [I > 2 σ (I)], R1 = 0.1007, wR2 = 0.2348, largest diff. peak and hole 0.688Å⁻³ and -0.438e'Å⁻³.

Crystal Structure of 2e



Figure 1 The X-Ray crystal structure of compound 2e

Crystal structure data for macrocycle 3d: CCDC 844754.

 $C_{10}H_9NO_5$, chemical formula weight: 227.69, Orthorhombic space group P2(1)/c, a = 9.077(5), b = 12.606(7), c = 9.405(5) Å; $\alpha = 90.00^{\circ}$, $\beta = 102.097()9^{\circ}$, $\gamma = 90.00^{\circ}$, U = 1052.3(10) Å3, T = 298(2) K, Z = 4, DC = 1.437 Mg/M³, $\mu = 0.118 \text{ mm}^{-1}$, $\lambda = 0.71073$ Å, F(000) 474, crystal size $0.20 \times 0.20 \times 0.20 \text{ mm}^3$, 1954 independent reflections[R(int) = 0.0300], reflections collected 10229, refinementmethod: full-matrix least-squares on F²: goodness-of-fit on F² 1.074, final R indices [I > 2 σ (I)], R1 = 0.0561, wR2 = 0.1588, largest diff. peak and hole 0.318Å⁻³ and -0.133e'Å⁻³.

Crystal Structure of 3d



Figure 1 The X-Ray crystal structure of compound 3d

5. Spectral data of compound 3a-3m, 5a-5f

2-oxo-2-phenylethyl formate (2a)



IR (KBr): 3425, 3064, 2933, 1731, 1693, 1598, 1450, 1288, 1234, 1171, 1103 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 8.26 (s, 1H), 7.93 (d, J = 7.8 Hz, 2H), 7.61-7.64 (t, J = 7.2 Hz, 1H), 7.49-7.52 (t, J = 7.8 Hz, 2H), 5.44 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =191.1, 160.0, 134.1, 133.9, 128.9, 127.8, 65.3;

HRMS (ESI): $m/z [M + H]^+$ calcd for C₉H₉O₃: 165.05369; found: 165.05462. 2-oxo-2-(p-tolyl)ethyl formate (**2b**)



IR (KBr): 3437, 3046, 2951, 1726, 1692, 1606, 1420, 1371, 1281, 1239, 1170, 1012 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.25 (s, 1H), 7.82 (d, J = 7.8 Hz, 2H), 7.28 (d, J = 7.8 Hz, 2H), 5.41 (s, 2H), 2.42 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =190.6, 160.0, 145.0, 131.1, 129.5, 127.8, 65.2, 21.7; HRMS (ESI):

 $\mbox{m/z} \left[M + H \right]^{+} \mbox{calcd for } C_{10} H_{10} O_3 \mbox{: } 179.0703 \mbox{; found: } 179.0711 \mbox{.}$

2-(4-methoxyphenyl)-2-oxoethyl formate (2c)



IR (KBr): 3413, 2944, 2847, 1731, 1682, 1601, 1572, 1512, 1464, 1424, 1372, 1316, 1267, 1111, 1014 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.25 (s, 1H), 7.89 (d, J = 7.8 Hz, 2H), 6.95 (d, J = 7.8 Hz, 2H), 5.40 (s, 2H), 3.87 (s, 3H) ; ¹³C

NMR (150 MHz, CDCl₃): δ =189.5, 164.0, 160.1, 130.0, 129.9, 114.0, 65.0, 55.4; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₀H₁₀O₄: 195.0652; found: 195.0143.

2-(2,4-dimethoxyphenyl)-2-oxoethyl formate (2d)



IR (KBr): 3411, 3314, 3097, 2953, 2844, 1729, 1665, 1605, 1478, 1421, 1370, 1336, 1289, 1258, 1219, 1111, 1017 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.25 (s, 1H), 8.00 (d, J = 8.4 Hz, 1H), 6.58 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 3.93 (s, 3H), 3.87 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =190.0, 165.6, 161.4, 160.4,

133.2, 117.3, 105.9, 97.9, 69.2, 55.6; HRMS (ESI): $m/z \ [M + H]^+$ calcd for $C_{11}H_{12}O_5$: 225.0757; found: 225.0753.

2-(4-nitrophenyl)-2-oxoethyl formate (2e)



IR (KBr): 3444, 3109, 2949, 1727, 1702, 1605, 1529, 1372, 1348, 1321, 1284, 1226, 1156, 1006 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 8.36 (d, J = 8.4 Hz, 2H), 8.26 (s, 1H), 8.11 (d, J = 8.4 Hz, 2H), 5.47 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =190.0, 159.8, 150.7, 138.2, 128.9, 124.1, 65.3; HRMS

(ESI): $m/z [M + H]^+$ calcd for C₉H₇NO₅: 210.0216; found: 210.0404.

2-(4-bromophenyl)-2-oxoethyl formate (**2f**)



IR (KBr): 3427, 3094, 2945, 1719, 1690, 1585, 1427, 1399, 1283, 1240, 1180, 1070, 1003 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.25 (s, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.65 (d, J = 8.4 Hz, 2H), 5.40 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ

=190.2, 159.9, 132.5, 132.3, 129.3, 129.2, 65.1; HRMS (ESI): $m/z [M + H]^+$ calcd for C₉H₇BrO₃: 290.9627; found: 290.9872.

2-(3,4-dichlorophenyl)-2-oxoethyl formate (**2g**)



IR (KBr): 3449, 3090, 3011, 2942, 1731, 1696, 1582, 1429, 1398, 1287, 1264, 1223, 1172, 1042 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.24 (s, 1H), 8.00 (s, 1H), 7.74 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1 H), 5.38 (s, 2H); ¹³C NMR (150 MHz, d6-DMSO): δ =189.2, 159.8, 138.8, 133.7, 133.3, 131.1, 129.8, 126.7,

65.0; HRMS (ESI): m/z $[M + H]^+$ calcd for C₉H₆Cl₂O₃: 234.9767; found: 234.9773.

2-(naphthalen-2-yl)-2-oxoethyl formate (2h)



IR (KBr): 3444, 3109, 2949, 1727, 1702, 1605, 1529, 1372, 1348, 1321, 1284, 1226, 1156, 1006 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.44 (s, 1H), 8.30 (s, 1H), 7.89-7.99 (m, 4H), 7.63-7.66 (t, J = 7.8 Hz, 1H), 7.58-7.60 (t, J = 7.8 Hz, 1H), 7.5

1H), 5.59 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =191.0, 160.1, 135.9, 132.3, 131.2, 129.6, 129.0, 128.9, 127.9, 127.1, 123.2, 65.4; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₃H₁₀O₃: 237.0522; found: 237.0520.

2-([1,1'-biphenyl]-4-yl)-2-oxoethyl formate (2i)



IR (KBr): 3419, 3036, 2943, 1728, 1697, 1604, 1447, 1422, 1402, 1373, 1286, 1237, 1167, 1005 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.27 (s, 1H), 7.99 (d, J = 7.8 Hz, 2H), 7.70 (d, J = 8.4 Hz, 2H), 7.62 (d, J = 7.8 Hz, 2H), 7.46-7.49 (t, J = 7.8 Hz, 2H), 7.40-7.43 (t, J = 7.8 Hz, 1H), 5.46 (s, 2H); ¹³C NMR (150

MHz, CDCl₃): δ =191.6, 160.0, 146.7, 139.4, 132.5, 129.0, 128.4, 127.5, 127.2, 65.3; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₅H₁₂O₃: 263.0679; found: 263.0677.

2-(furan-2-yl)-2-oxoethyl acetate (2j)



IR (KBr): 3422, 3131, 2929, 2856, 1730, 1688, 1570, 1468, 1399, 1276, 1161, 1021 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.23 (s, 1H), 7.65 (d, J = 1.2 Hz, 1H), 7.31 (d, J = 3.6 Hz, 1H), 6.60-6.61 (q, J = 1.8 Hz, 1H), 5.29 (s, 2H); ¹³C NMR

(150 MHz, CDCl₃): δ =180.5, 159.9, 150.1, 146.9, 117.9, 112.5, 64.4; HRMS (ESI): m/z [M + H]⁺ calcd for C₇H₆O₄: 192.9930; found: 192.9979.

2-oxo-2-(thiophen-2-yl)ethyl acetate (2k)



IR (KBr): 3429, 3096, 3001, 2942, 1724, 1671, 1520, 1413, 1387, 1274, 1252, 1194, 1059 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.24 (s, 1H), 7.77 (d, J = 4.2 Hz, 1H), 7.74 (d, J = 4.2 Hz, 1H), 7.18-7.19 (q, J = 4.2 Hz, 1H), 5.34 (s, 1H); ¹³C NMR (150 MHz, CDCl₃): δ =180.5, 159.9, 150.1, 146.9, 117.9, 112.5, 64.4;

HRMS (ESI): $m/z [M + H]^+$ calcd for $C_7H_7SO_3$: 171.00996; found: 171.01104.

2-(benzofuran-2-yl)-2-oxoethyl formate (2l)



IR (KBr): 3414, 2926, 1723, 1695, 1609, 1562, 1189, 1157, 1138 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.26 (s, 1H), 7.72 (d, J = 7.2 Hz, 1H), 7.61 (d, J = 7.2 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.50-7.52 (t, J = 7.2 Hz, 1H) , 7.32-7.36 (q, J = 7.2 Hz, 1H), 5.43 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ

=182.6, 159.9, 155.5, 150.0, 128.8, 126.5, 124.2, 123.5, 113.6, 112.4, 65.0; HRMS (ESI): $m/z [M + H]^+$ calcd for C₁₁H₉O₄: 205.04858; found: 205.04954.

2-(1H-indol-3-yl)-2-oxoethyl formate (2m)



IR (KBr): 3237, 2931, 1729, 1649, 1579, 1520, 1425, 1313, 1238, 1195, 1156 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): $\delta = 8.76$ (s, 1H), 8.33 (s, 1H), 8.29 (s, 1H), 7.94 (s, 1H), 7.45 (s, 1H), 7.33 (s, 1H), 5.31 (s, 2H) ; ¹³C NMR (150 MHz, d6-DMSO): $\delta = 187.1$, 161.9, 136.3, 133.8, 125.3, 123.3, 122.2, 121.2, 112.8,

112.4, 65.5; HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{11}H_9NO_3$: 204.0655; found: 204.0653.

2-(4-hydroxyphenyl)-2-oxoethyl formate (2n)



IR (KBr): 3349, 2923, 1727, 1677, 1604, 1577, 1515, 1432, 1370, 1352, 1289, 1250, 1217, 1192, 1168, 1034, 951, 847 cm⁻¹; ¹H NMR (600 MHz, DMSO): $\delta = 10.58$ (s, 1H), 8.40 (s, 1H), 7.86 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 9.0 Hz, 2H), 5.49 (s, 2H); ¹³C NMR (150 MHz, d6-DMSO): $\delta = 190.3$, 162.6,

161.7, 130.5, 125.4, 115.6, 115.5, 65.6; HRMS (ESI): $m/z [M + H]^+$ calcd for C₉H₈O₄: 181.0495; found: 181.0501.

(E)-2-oxo-4-phenylbut-3-en-1-yl formate (20)



IR (KBr): 3435, 3060, 3029, 2934, 1730, 1685, 1613, 1576, 1495, 1450, 1376, 1332, 1268, 1170, 1091, 1053 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.21 (s, 1H), 7.67 (d, J = 16.2 Hz, 1H), 7.55 (d, J =9.0 Hz, 2H), 7.38-7.41 (m, 3H), 6.79 (d, J = 16.2 Hz, 1H), 5.03 (s, 2H), 2.39 (s, 3H); ¹³C NMR (150 MHz,

CDCl₃): δ =191.3, 160.0, 144.5, 133.8, 131.1, 129.0, 128.5, 121.1, 66.5; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₂H₁₂O₃: 191.0703; found: 191.0865.

(E)-2-oxo-4-(p-tolyl)but-3-en-1-yl formate (2p)



IR (KBr): 3440, 2942, 1728, 1690, 1599, 1511, 1415, 1372, 1270, 1167, 1087, 1037 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.23 (s, 1H), 7.65-7.68 (q, J = 16.2 Hz, 1H), 7.46 (d, J =7.8 Hz, 2H), 7.21 (d, J = 7.8 Hz, 2H), 6.75-6.78 (q,

 $J = 16.2 \text{ Hz}, 1\text{H}, 5.03 \text{ (s, 2H)}, 2.39 \text{ (s, 3H)}; {}^{13}\text{C NMR} (150 \text{ MHz}, \text{CDCl}_3): \delta = 191.3, 160.0, 144.6, 141.8, 131.1, 129.8, 128.5, 120.1, 66.5, 21.5; \text{HRMS (ESI)}: \text{m/z } [\text{M} + \text{Na}]^+ \text{ calcd for } \text{C}_{12}\text{H}_{12}\text{O}_3: 227.0679; found: 227.5765.}$

(E)-4-(4-methoxyphenyl)-2-oxobut-3-en-1-yl formate (**2q**)



IR (KBr): 3445, 2934, 2837, 1671, 1594, 1511, 1421, 1209, 1254, 1172, 1095, 1025 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ =8.15 (s, 1H), 7.58 (d, J = 15.6 Hz, 1H), 7.45 (d, J =8.8 Hz, 2H), 7.85 (d, J =8.4 Hz, 2H), 6.61 (d, J =

16.4 Hz, 1H), 4.96 (d, J = 8.4 Hz, 2H), 3.79 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ =191.2, 162.1, 160.0, 144.3, 130.4, 126.5, 118.8, 114.5, 66.6, 55.4; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₂H₁₂O₄: 2243.0628; found: 243.0651.

(E)-4-(3,4-dimethoxyphenyl)-2-oxobut-3-en-1-yl formate (2r)

 $\begin{array}{c} \begin{array}{c} & & \\ & & & \\ & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & & \\ & & & \\ &$

(E)-4-(4-(benzyloxy)-3-methoxyphenyl)-2-oxobut-3-en-1-yl formate (2s)

IR (KBr): 3442, 2943, 1724, 1676, 1619, 1593, 1515, 1469, 1425, 1384, 1271, 1235, 1141, 1087, 1034

cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ =8.21 (s, 1H), 7.61 (d, J = 16.2 Hz, 1H), 7.38-7.36 (t, J = 7.2 Hz, 2H), 7.32 (d, J = 7.2 Hz, 1H), 7.08 (s, 2H), 6.88 (d, J = 8.4 Hz, 1H), 6.66 (d, J = 16.2 Hz, 1H), 5.19 (s, 2H), 5.01 (s, 2H), 3.92 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =191.1, 159.9, 151.0, 149.7, 144.5,

136.3, 128.6, 128.0, 127.1, 123.3, 119.1, 113.3, 110.4, 70.7, 66.5, 56.0; HRMS (ESI): $m/z \ [M + H]^+$ calcd for $C_{19}H_{18}O_5$: 349.1046; found: 349.1040.

(E)-4-(4-(dimethylamino)phenyl)-2-oxobut-3-en-1-yl formate (2t)

IR (KBr): 3437, 2925, 1725, 1688, 1666, 1580, 1528, 1436, 1370, 1268, 1227, 1173, 1144, 1083 cm⁻¹;



¹H NMR (600 MHz, CDCl₃): δ =8.23 (s, 1H), 7.64 (d, J = 16.2 Hz, 1H), 7.46 (d, J = 9.0 Hz, 2H), 6.67 (d, J = 9.0 Hz, 2H), 6.61 (d, J = 16.2 Hz, 1H), 5.01 (s, 2H), 3.05 (s, 6H); ¹³C NMR (150 MHz, CDCl₃): δ =191.1, 160.1, 152.3, 145.4, 130.6, 121.5, 115.8, 111.8, 66.5, 40.1; HRMS (ESI): m/z [M + H]⁺

calcd for C₁₃H₁₃NO₃: 256.0944; found: 256.0940.

(E)-4-(3-nitrophenyl)-2-oxobut-3-en-1-yl formate $(\mathbf{2u})$



IR (KBr): 3436, 3071, 2929, 1727, 0718, 1680, 1629, 1526, 1430, 1354, 1206, 1171, 1099 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 8.40 (s, 1H), 8.23 (d, J = 7.8 Hz, 1H), 8.21 (s, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 16.2 Hz, 1H), 7.60-7.69 (t, J = 7.8 Hz, 1H), 6.93 (d, J = 16.8 Hz, 1H), 5.04 (s, 2H); ¹³C NMR

(150 MHz, CDCl₃): δ =191.0, 159.9, 159.8, 148.6, 141.4, 135.6, 134.2, 130.1, 125.1, 123.4, 122.6, 122.5, 66.8; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₁H₁₀NO₅: 236.05444; found: 236.05535. (F) A (A mitranel equal) 2 conclusion 2 conclusion (257)

(E)-4-(4-nitrophenyl)-2-oxobut-3-en-1-yl formate (2v)



IR (KBr): 3421, 3112, 3065, 2931, 1718, 1681, 1593, 1513, 1343, 1178, 1106 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 8.28 (d, J = 8.4 Hz, 2H), 8.24 (s, 1H), 7.74 (d, J = 8.4 Hz, 3H), 6.94 (d, J = 15.6 Hz, 1H), 5.06 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): δ =191.0, 159.8, 148.8, 141.4, 140.0, 129.1,

124.4, 124.3, 66.8; HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{11}H_9NO_5$: 236.0553; found: 236.0558.

(E)-4-(4-hydroxyphenyl)-2-oxobut-3-en-1-yl formate (**2w**)



IR (KBr): 3380, 2925, 2855, 1729, 1682, 1584, 1515, 1453, 1379, 1286, 1171, 1024 cm⁻¹; ¹H NMR (600 MHz, DMSO): $\delta = 10.21$ (s, 1H), 8.39 (s, 1H), 7.65 (d, J = 16.8 Hz, 1H), 7.61 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 7.8 Hz, 2H), 6.79 (d, J = 16.8 Hz, 1H), 5.15 (s, 2H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 192.0$, 160.3,

143.9, 130.9, 125.2, 119.0, 116.0, 66.8; HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{11}H_{10}O_4$: 229.0471; found: 229.0782.

(E)-4-(4-bromophenyl)-2-oxobut-3-en-1-yl formate (2x)



IR (KBr): 3433, 2998, 2934, 1725, 1666, 1620, 1584, 1486, 1428, 1391, 1285, 1261, 1190, 1164, 1072, 1008 cm⁻¹; ¹H NMR (600 MHz, DMSO): δ = 8.22 (s, 1H), 7.62 (d, J = 16.2 Hz, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 16.2 Hz, 1H), 5.02 (s, 2H); ¹³C NMR (150

MHz, CDCl₃): δ =191.2, 159.9, 143.1, 132.7, 132.3, 129.8, 125.5, 121.5, 66.6; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₁H₉BrO₃: 29.09627; found: 290.9631.

2-oxo-2-phenylethyl acetate (3a)



IR (KBr): 3472, 3064, 2937, 1750, 1703, 1597, 1448, 1422, 1375, 1221, 1085, 998 cm⁻¹; ¹H NMR (600 MHz, CDCl₃): δ = 7.92 (d, J = 8.4 Hz, 2H), 7.59-7.63 (t, J = 7.2 Hz, 1H), 7.47-4.51 (t, J = 7.2 Hz), 5.35 (s, 2H), 2.23 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ =192.1, 170.4, 134.0, 133.8, 128.8, 127.7, 66.0, 20.5;

HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{10}H_{11}O_3$: 179.07027; found: 179.06977.

2-oxo-2-(p-tolyl)ethyl acetate (**3b**)



IR (KBr): 3465, 2954, 1749, 1699, 1605, 1420, 1372, 1289, 1226, 1180, 1085, 1051 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.74 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 8.0 Hz, 2H), 5.25 (s, 2H), 5.35 (s, 3H), 2.16 (s, 3H),; ¹³C NMR (100 MHz, CDCl₃): δ =191.7, 144.8, 131.6, 129.5, 129.4, 128.7, 127.8, 65.9, 21.7, 20.6;

HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{11}H_{12}O_3$: 215.0679; found: 215.0680. 2-(4-methoxyphenyl)-2-oxoethyl acetate (**3c**)



IR (KBr): 3465, 3040, 2954, 1926, 1749, 1696, 1605, 1571, 1420, 1372, 1289, 1226, 1180, 1085, 1051 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.89-7.92 (m, 2H), 7.95-7.98 (m, 2H), 5.31 (s, 2H), 3.89 (s, 3H), 2.24 (s, 3H); ¹³C NMR (150 MHz, CDCl₃): δ = 190.6, 170.5, 164.0, 130.0, 127.1, 65.7, 55.5, 20.6; HRMS

(ESI): $m/z [M + H]^+$ calcd for $C_{11}H_{13}O_4$: 209.07980; found: 209.08084. 2-(4-nitrophenyl)-2-oxoethyl acetate (**3d**)



IR (KBr): 3478, 3119, 2926, 2855, 1748, 1703, 1603, 1524, 1416, 1373, 1348, 1319, 1284, 1248, 1218, 1107, 1081 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 8.35 (d, J = 8.0 Hz, 2H), 8.09 (d, J = 8.0 Hz, 2H), 5.34 (s, 2H), 2.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.0, 170.3, 150.7, 138.6, 128.9, 124.1, 66.0,

29.7, 20.5; HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{10}H_{10}NO_5$: 224.05463; found: 224.05535. 2-(4-bromophenyl)-2-oxoethyl acetate (**3e**)



IR (KBr): 3487, 3376, 2990, 2950, 1746, 1694, 1585, 1430, 1398, 1378, 1292, 1225, 1069 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.77-7.80 (m, 2H), 7.63-7.65 (m, 2H), 5.30 (s, 2H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.3, 170.3, 132.8, 132.2, 129.2, 129.1, 65.8, 20.5; HRMS (ESI): m/z [M

+ H]⁺ calcd for C₁₀H₉BrO₃: 278.9627; found: 278.9631.

2-(furan-2-yl)-2-oxoethyl acetate (3f)



IR (KBr): 3484, 3135, 2942, 1751, 1693, 1572, 1469, 1421, 1400, 1374, 1229, 1162, 1080, 1029 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.62 (d, J = 2.4 Hz, 1H), 7.29 (d, J = 4.0 Hz, 1H), 6.58-6.59 (q, J = 2 Hz, 1H), 5.19 (s, 2H), 2.22 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 181.7, 170.3, 150.5, 146.7, 117.7, 112.5, 65.3, 20.5; HRMS (ESI): m/z [M + H]⁺ calcd for

C₈H₈O₄: 191.0315; found: 191.0312.

2-oxo-2-(thiophen-2-yl)ethyl acetate (3g)



IR (KBr): 3484, 3135, 2942, 1751, 1693, 1572, 1469, 1421, 1400, 1374, 1229, 1162, 1080, 1029 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.76 (d, J = 2.4 Hz, 1H), 7.71 (d, J = 4.8 Hz, 1H), 7.16-7.18 (t, J = 4.4 Hz, 1H), 5.23 (s, 2H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 185.4, 170.3, 134.3, 131.9, 128.2, 65.7,

20.5; HRMS (ESI): $m/z [M + H]^+$ calcd for $C_8H_8O_3S$: 207.0086; found: 207.0082.

2-(naphthalen-2-yl)-2-oxoethyl acetate (3h)



IR (KBr): 3466, 3062, 2943, 1750, 1696, 1624, 1592, 1467, 1417, 1375, 1235, 1176, 1081, 1026, 1008 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 8.41 (s, 1H), 7.951-7.976 (q, J = 8.4 Hz, 2H), 7.891-7.938 (t, J = 8.4 Hz, 1H), 7.56-7.62 (m, 2H), 5.47 (s, 2H), 2.25 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 192.1, 170.5,

135.9, 132.3, 131.5, 129.5, 128.8, 127.8, 127.0, 123.2, 66.1, 20.6; HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{14}H_{12}O_3$: 251.0679; found: 251.0885.

(E)-2-oxo-4-phenylbut-3-en-1-yl acetate (3o)



IR (KBr): 3457, 2932, 1751, 1705, 1688, 1615, 1450, 1419, 1377, 1232, 1195, 1051 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.67 (d, J = 16.4 Hz, 1H), 7.55-7.58 (q, J = 6.8 Hz, 2H), 6.79 (s, J = 16.0 Hz, 1H), 4.95 (s, 3H), 2.22 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 192.41, 170.3, 144.2, 134.0, 131.0, 129.0, 128.5, 121.5,

67.4, 20.6; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₂H₁₂O₃: 227.0679; found: 227.5765. (E)-4-(4-(benzyloxy)-3-methoxyphenyl)-2-oxobut-3-en-1-yl acetate (**3r**)



IR (KBr): 3452, 3016, 2923, 1724, 1680, 1620, 1513, 1454, 1424, 1384, 1367, 1326, 1271, 1226, 1200, 1168, 1137, 1066, 1025 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.60 (d, J = 16.0 Hz, 1H), 7.43 (d, J = 7.2 Hz, 2H), 7.36-7.40 (m, 2H), 7.33 (d, J = 7.2 Hz, 1H), 7.071-7.091 (q, J = 6.0 Hz, 1H), 6.89 (d, J = 9.2 Hz, 1H),

6.64 (d, J = 16.0 Hz, 1H), 5.21 (s, 2H), 4.94 (s, 2H), 3.93 (s, 3H), 2.22 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 192.1, 170.4, 150.9, 149.7, 144.1, 136.3, 128.7, 128.1, 127.2, 123.2, 119.5, 113.3, 110.3, 70.8, 67.2, 56.0, 20.6; HRMS (ESI): m/z [M + H]⁺ calcd for C₂₀H₂₀O₅: 341.1384; found: 341.1387. (E)-4-(3,4-dimethoxyphenyl)-2-oxobut-3-en-1-yl acetate (**3s**)



IR (KBr): 3444, 2998, 2916, 1837, 1736, 1696, 1593, 1512, 1466, 1424, 1378, 1263, 1162, 1143, 1112, 1052, 1021 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 7.62 (d, J = 16.4 Hz, 1H), 7.16 (d, J = 8.4 Hz, 2H), 6.88 (d, J = 8.4 Hz, 1H), 6.66 (d, J = 15.6 Hz, 1H), 4.96 (s, 2H), 3.93 (s, 6H), 2.22 (s, 3H); ¹³C NMR

(100 MHz, CDCl₃): $\delta = 192.1$, 170.4, 150.9, 149.7, 144.1, 136.3, 128.7, 128.1, 127.2, 123.2, 119.5,

113.3, 110.3, 70.8, 67.2, 56.0, 20.6; HRMS (ESI): $m/z [M + H]^+$ calcd for $C_{14}H_{16}O_5$: 287.0890; found: 287.0888.

(E)-4-(3-nitrophenyl)-2-oxobut-3-en-1-yl acetate ($\mathbf{3v}$)



IR (KBr): 3460, 3067, 2927, 2855, 1740, 1667, 1630, 1528, 1439, 1384, 1351, 1250, 1199, 1068 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 8.42 (s, 1H), 8.26 (d, J = 7.2 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.71 (d, J = 16.04 Hz, 1H), 7.612-7.685 (t, J = 8.4 Hz, 1H), 6.91 (d, J = 16.4 Hz, 2H), 4.95 (s, 1H), 2.23 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 192.0, 141.1, 134.2, 130.1, 125.1, 123.7, 122.6,

67.6, 20.5; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₂H₁₂NO₅: 250.07035; found: 250.07100. (E)-4-(4-nitrophenyl)-2-oxobut-3-en-1-yl acetate (**3w**)



IR (KBr): 3443, 2927, 1740, 1702, 1621, 1594, 1513, 1415, 1349, 1265, 1235, 1115, 1058, 1002cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ = 8.27 (d, J = 7.6 Hz, 2H), 7.72 (d, J = 7.2 Hz, 2H), 7.68 (s, 1H), 6.90 (d, J = 16.4 Hz, 1H), 2.23 (s, 3H); ¹³C

NMR (100 MHz, CDCl₃): δ = 191.9, 170.2, 148.8, 141.0, 140.1, 129.0, 124.8, 124.2, 67.6, 20.5; HRMS (ESI): m/z [M + H]⁺ calcd for C₁₂H₁₂NO₅: 250.07035; found: 250.07100.

7. Appendix: spectral Copies of ¹H NMR and ¹³C NMR of compounds obtained in this Study













































































